Final analysis of the real-world GioTag study

Final analysis of the real-world GioTag study


GIOTRIF® (afatinib) is an irreversible ErbB inhibitor approved in non-small-cell lung cancer. Find out how your patients could benefit.

Giotrif-afatinib indication lung
Indication Read More


GIOTRIF® (afatinib) dose modification can be an important strategy to help manage adverse reactions.

Giotrif-afatinib Dosing
Dosing Read More

AE management

Common AEs associated with GIOTRIF® (afatinib) are generally well managed with supportive care.

Giotrif-afatinib AE management
AE management Read More
Giotrif-afatinib clinical trial

Clinical trial data

Learn more about the LUX-Lung clinical trial programme and explore the clinical trial data for afatinib.

Clinical trial data Read More
Giotrif-afatinib real world evidence

Real-world evidence

Read the real-world evidence for GIOTRIF® (afatinib) use, demonstrating effectiveness in clinical practice.

Real-world evidence Read More